Vericel Corporation (VCEL)
Company Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States.
The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.
Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
The company was formerly known as Aastrom Biosciences, Inc.
Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Country | United States |
IPO Date | Feb 4, 1997 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 357 |
CEO | Dominick C. Colangelo Esq. |
Contact Details
Address: 64 Sidney Street Cambridge, Massachusetts United States | |
Website | https://vcel.com |
Stock Details
Ticker Symbol | VCEL |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000887359 |
CUSIP Number | 92346J108 |
ISIN Number | US92346J1088 |
Employer ID | 94-3096597 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dominick C. Colangelo Esq. | Chief Executive Officer, President & Director |
Joseph Anthony Mara Jr. | Chief Financial Officer & Treasurer |
Michael Halpin | Chief Operating Officer |
Sean C. Flynn | Chief Legal Officer |
Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B. | Chief Medical Officer |
Eric Burns | Vice President of Finance & Investor Relations |
Jonathan D. Siegal | Principal Accounting Officer, Vice President & Corporate Controller |
Karen Mahoney | Chief Human Resources Officer |
Patrick Helfrich | Vice President of Marketing & Commercial Strategy |
Patrick J. Fowler | Senior Vice President of Corporate Development & Strategy |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 20, 2025 | DEFA14A | Filing |
Mar 20, 2025 | DEF 14A | Filing |
Mar 20, 2025 | ARS | Filing |
Mar 14, 2025 | 4 | Filing |
Mar 05, 2025 | 4 | Filing |
Mar 05, 2025 | 4 | Filing |
Mar 05, 2025 | 4 | Filing |
Mar 05, 2025 | 4 | Filing |
Feb 27, 2025 | 10-K | Annual Report |
Feb 27, 2025 | 8-K | Current Report |